[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338101-105":59,"doc-detail-338101-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","the-prognostic-and-predictive-utility-of-cdx2-in-colorectal-cancer","The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer","","Caudal type homeobox transcription factor 2 (CDX2) functions as a gastrointestinal cancer biomarker involved in epithelial development and differentiation. Low or absent CDX2 has been linked to poor prognosis and proposed as a predictor of chemotherapy response. Tissue samples from 668 patients with stage I–IV colorectal cancer were stained for CDX2 and grouped by expression level. Low CDX2 staining (7.9%) correlated with poorer differentiation and lymphovascular or perineural invasion. Low expression reduced overall and disease-free survival, and multivariable analysis confirmed independent prognostic value; predictive value for chemotherapy was not established.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-prognostic-and-predictive-utility-of-cdx2-in-colorectal-cancer/338101/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-prognostic-and-predictive-utility-of-cdx2-in-colorectal-cancer/338101.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is CDX2 and why is it relevant to colorectal cancer?","Question",{"text":112,"@type":113},"CDX2 is a transcription factor expressed in intestinal epithelium that regulates cell growth. In colorectal cancer, CDX2 can be downregulated or lost, affecting tumor behavior and treatment response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was CDX2 expression assessed in the study?",{"text":117,"@type":113},"Tumor tissue samples from 668 patients with stage I–IV colorectal cancer were stained for CDX2. Samples were stratified into subgroups based on expression levels, and statistical tests evaluated links to survival and chemotherapy response.",{"name":119,"@type":110,"acceptedAnswer":120},"Does low CDX2 expression predict survival outcomes?",{"text":121,"@type":113},"Yes. Patients with low CDX2 expression showed reduced overall survival and disease-free survival, and multivariable analysis supported CDX2 as an independent poor prognostic factor.",{"name":123,"@type":110,"acceptedAnswer":124},"Was adjuvant chemotherapy beneficial for early-stage colon cancer patients with low CDX2?",{"text":125,"@type":113},"No statistically significant improvement in survival was observed for stage II colon cancer with low CDX2 levels, and no relationship between CDX2 levels and therapy response was found in the rectal cohort.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},338101,1790093733,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nThe Prognostic and Predictive Utility of CDX2 in Colorectal Cancer  \nWei Yen Chan 1,2, Wei Chua 1,2,3, Kate Wilkinson 1,2, Chandika Epitakaduwa 4, Hiren Mandaliya 5, Joseph Descallar 3,6, Tara Laurine Roberts 2,3, Therese Maria Becker 2,3,6, Weng Ng 1,2,3, Cheok Soon Lee 2,3,4,6 and Stephanie Hui-Su Lim 2,3,5, *  \nCitation: Chan, W.Y.; Chua, W.; Wilkinson, K.; Epitakaduwa, C.; Mandaliya, H.; Descallar, J.; Roberts, T.L.; Becker, T.M.; Ng, W.; Lee, C.S.; et al. The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer. Int. J. Mol. Sci. 2024, 25, 8673 .  \n[https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25168673  \nAcademic Editors: Matin Sheriff and Stergios Boussios  \nReceived: 18 July 2024  \nRevised: 3 August 2024  \nAccepted: 4 August 2024  \nPublished: 8 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Liverpool Cancer Therapy Centre, Liverpool Hospital, Liverpool, NSW 2170, Australia; [weiyen_chan@hotmail.com](weiyen_chan@hotmail.com) (W.Y.C.); [wei.chua@health.nsw.gov.au](wei.chua@health.nsw.gov.au) (W.C.); [kate.wilkinson1@health.nsw.gov.au](kate.wilkinson1@health.nsw.gov.au) (K.W.)  \n2 School of Medicine, Western Sydney University, Locked Bag 1797, Penrith, NSW 2571, Australia; [tara.roberts@westernsydney.edu.au](tara.roberts@westernsydney.edu.au) (T.L.R.); [therese.becker@inghaminstitute.org.au](therese.becker@inghaminstitute.org.au) (T.M.B.); [soon.lee@westernsydney.edu.au](soon.lee@westernsydney.edu.au) (C.S.L.)  \n3 Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia; [joseph.descallar@health.nsw.gov.au](joseph.descallar@health.nsw.gov.au)  \n4 Department of Anatomical Pathology, Liverpool Hospital, Liverpool, NSW 2170, Australia; [dilanchandika@gmail.com](dilanchandika@gmail.com)  \n5 Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, NSW 2560, Australia; [hiren.mandaliya@calvarymater.org.au](hiren.mandaliya@calvarymater.org.au)  \n6 Faculty of Medicine, South Western Sydney Clinical School, The University of New South Wales, Liverpool, NSW 2170, Australia  \n* Correspondence: [stephanie.lim@health.nsw.gov.au](stephanie.lim@health.nsw.gov.au)  \nSimple Summary: Caudal type homeobox transcription factor 2 (CDX2) is a protein expressed in the normal intestinal epithelium that is essential for regulating cell growth. It has been found to be downregulated or lost in a significant proportion of patients with colorectal cancer and can influence cancer behaviour and treatment response. Therefore, further research and assessment of CDX2 levels in tumour tissues is crucial for identifying potential markers that can select patients with worse outcomes and guide treatment decisions to improve survival. This study found that tumours with low CDX2 expression were associated with more aggressive features of cancer and worse outcomes for patients. However, giving additional chemotherapy after surgery to certain early-stage colon cancer patients with low CDX2 levels did not significantly improve survival. These findings support CDX2 as a marker for colorectal cancer prognosis, but more research is needed to determine its ability to predict chemotherapy outcomes.  \nAbstract: Caudal type homeobox transcription factor 2 (CDX2) is a gastrointestinal cancer biomarker that regulates epithelial development and differentiation. Absence or low levels of CDX2 have been associated with poor prognosis and proposed as a chemotherapy response predictor. Tumour tissue samples from 668 patients with stage I–IV colorectal cancer were stained for CDX2 and stratified into two subgroups according to expression levels. Statistical tests wer","cbCaiidPeMKEjOVu","https://ap.wps.com/l/cbCaiidPeMKEjOVu","pdf",1827023,15,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What is CDX2 and why is it relevant to colorectal cancer?\",\"answer\":\"CDX2 is a transcription factor expressed in intestinal epithelium that regulates cell growth. In colorectal cancer, CDX2 can be downregulated or lost, affecting tumor behavior and treatment response.\"},{\"question\":\"How was CDX2 expression assessed in the study?\",\"answer\":\"Tumor tissue samples from 668 patients with stage I–IV colorectal cancer were stained for CDX2. Samples were stratified into subgroups based on expression levels, and statistical tests evaluated links to survival and chemotherapy response.\"},{\"question\":\"Does low CDX2 expression predict survival outcomes?\",\"answer\":\"Yes. Patients with low CDX2 expression showed reduced overall survival and disease-free survival, and multivariable analysis supported CDX2 as an independent poor prognostic factor.\"},{\"question\":\"Was adjuvant chemotherapy beneficial for early-stage colon cancer patients with low CDX2?\",\"answer\":\"No statistically significant improvement in survival was observed for stage II colon cancer with low CDX2 levels, and no relationship between CDX2 levels and therapy response was found in the rectal cohort.\"}]","The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer | PDF",1790021963,38,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98bec58d6027690f5de01fafa0264594.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/468abac33a96433772fc7f9c6c0f71d2.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/105472555912eb2bb4629f5a09846a06.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba423e5eb900b58f6bbeba3f196bb19b.webp",980,1385]